The CLINGLIO project aims to advance a novel drug, 2OHOA, for the treatment of glioblastoma towards an initial market entry in Europe. For this purpose, the CLINGLIO project will encompass a demonstrative phase IIB clinical study to evaluate the efficacy of an innovative therapy, based on 2OHOA and SoC in subjects with primary newly diagnosed glioblastoma. In addition, planned studies with patient samples and glioma cells have the objective to further characterize biomarkers for predictive (diagnosis and prognosis with threshold biomarkers and omics signatures), pharmacodynamic/pharmacogenomic and stratification (patient treatment assignation) purposes.